Chimeric Antigen Receptor (CAR)-T cell therapy is a therapeutic approach whereby T-cells are engineered with a synthetic receptor for increased tumor targeting specificity and tumor cytotoxicity.
The central image depicts currently used strategies for clinical targeting of TGF-β. Below are methods applicable from preclinical screening to clinical practice, including using humanized mouse ...
The diagram highlights: clonal tumor populations comprising multiple molecular subtypes, contributing to BTCs heterogeneity. Distinct TME components, including: cancer-associated fibroblasts (CAFs) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results